Nan-Kwon Lee
Korea University · Medicine
About the Lab
Professor Nan-Kwon Lee's research lab specializes in clinical oncology, with a focus on optimizing treatment strategies for various cancers through multimodal therapy. The lab investigates the impact of molecular markers—such as PIK3CA mutations—on treatment response and survival outcomes in HER2-positive breast cancer, as well as the role of adjuvant radiation in locoregionally advanced thyroid and lymphoid malignancies. Research also emphasizes treatment delivery integrity, including radiation therapy interruption and completion, particularly in elderly patients and those receiving curative or palliative intent therapy. The lab integrates clinical data with translational insights to improve patient outcomes in gastrointestinal, head and neck, and breast cancers.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15OBJECTIVES: To investigate the role of adjuvant radiation therapy in locoregional control in patients with locoregionally advanced papillary thyroid carcinoma (pT4 or pN1b) based on a comparison of a group that received radiation therapy and a group that did not receive radiation therapy. METHODS: A retrospective analysis was performed on 165 patients with locoregionally advanced papillary thyroid carcinoma who underwent treatment between 2002 and 2011. Of these, 32 patients received adjuvant ra
PURPOSE: Mutations in the PIK3CA gene occur frequently in breast cancer patients. Activating PIK3CA mutations confer resistance to human epidermal growth factor receptor 2 (HER2)-targeted treatments. In this study, we investigated whether PIK3CA mutations were correlated with treatment response or duration in patients with HER2-positive (HER2+) breast cancer. Materials and Methods: We retrospectively reviewed the clinical information of patients with HER2+ breast cancer who received HER2-targete
BACKGROUND: The purpose of this report is to summarize our clinical experience of patients with stage I/II extranodal natural killer (NK)/T-cell lymphoma, nasal type, treated using sequential chemotherapy followed by radiotherapy (SCRT) or concurrent chemoradiotherapy (CCRT). METHODS: Forty-three patients with stage I/II extranodal NK/T-cell lymphoma, nasal type, who received SCRT (16 patients) or CCRT (27 patients) were included in the present analysis. RESULTS: The median follow-up time was 39
Local excision following preoperative chemoradiotherapy may be an alternative treatment for highly selected patients with locally advanced rectal cancer who have achieved ypT0-1 after preoperative chemoradiotherapy.
Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.
AIM: Our study analyzed the frequency and causes of treatment interruption among patients undergoing radiation therapy (RT). METHODS: A total of 1637 RT courses in 1500 patients were reviewed from September 2009 to October 2013. A continuous break over 7 days or a discontinuous break over 14 days was regarded as a temporary break and RT under 80% of planned treatment was regarded as incomplete. RESULTS: Two-hundred and twenty courses (13.4%) with treatment interruption were identified. Half of t
Research Areas
Dive deeper into Nan-Kwon Lee's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.